title: TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
abstract: BACKGROUND
  Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.
  
  
  METHODS
  Patients with epithelial ovarian cancer who presented for primary surgery were included in this study. A total of 148 serum samples from 37 patients were analyzed. Samples were prospectively collected at 4 predefined time points: 1. before radical debulking surgery, 2. after surgery and before platinum/taxane based chemotherapy, 3. during chemotherapy, 4. after chemotherapy. Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.
  
  
  RESULTS
  Serum levels of all markers changed substantially during first-line therapy. High CA-125 (p = 0.002), TIMP-1 (p = 0.007) and VEGF-165 (p = 0.02) after chemotherapy were associated with reduced overall survival. In addition, elevated CA-125 (p < 0.001) and VEGF-165 (p = 0.006) at this time point predicted poor progression-free survival. TIMP-1 and VEGF-165 were closely correlated at all time-points during therapy.
  
  
  CONCLUSIONS
  TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis. These findings support the role of angiogenesis in ovarian cancer progression and the use of antiangiogenic therapy.
authors.affiliation: Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Sven.Mahner@gmx.de
authors.forename: Sven
authors.initials: S
authors.lastname: Mahner
authors.forename: Linn
authors.initials: L
authors.lastname: Woelber
authors.forename: Christine
authors.initials: C
authors.lastname: Eulenburg
authors.forename: Joerg
authors.initials: J
authors.lastname: Schwarz
authors.forename: Walter
authors.initials: W
authors.lastname: Carney
authors.forename: Fritz
authors.initials: F
authors.lastname: Jaenicke
authors.forename: Karin
authors.initials: K
authors.lastname: Milde-Langosch
authors.forename: Volkmar
authors.initials: V
authors.lastname: Mueller
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000098:blood supply / Q000401:mortality / Q000628:therapy*; D017671:Platinum Compounds / Q000008:administration & dosage; D011446:Prospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D017671:Platinum Compounds; D043823:Taxoids; D019715:Tissue Inhibitor of Metalloproteinase-1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
references.citation: Gynecol Oncol. 2005 Dec;99(3):656-63
references.pmid: 16112717
references.citation: Gynecol Oncol. 2000 Jun;77(3):369-76
references.pmid: 10831344
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Anticancer Res. 1999 Mar-Apr;19(2B):1401-5
references.pmid: 10365113
references.citation: Int J Oncol. 2000 Oct;17(4):673-81
references.pmid: 10995877
references.citation: Cancer. 2009 Mar 15;115(6):1234-44
references.pmid: 19189349
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Crit Rev Oncol Hematol. 2009 Jan;69(1):12-27
references.pmid: 18595727
references.citation: Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81
references.pmid: 16343244
references.citation: Cancer. 1999 Jan 1;85(1):178-87
references.pmid: 9921991
references.citation: Nat Clin Pract Oncol. 2008 Apr;5(4):194-204
references.pmid: 18268546
references.citation: Br J Cancer. 1997;76(9):1221-7
references.pmid: 9365173
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1419-25
references.pmid: 19224846
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9
references.pmid: 16515588
references.citation: Obstet Gynecol. 1992 Jun;79(6):1002-10
references.pmid: 1579296
references.citation: J Clin Oncol. 2008 Jan 1;26(1):76-82
references.pmid: 18165643
references.citation: Nat Rev Cancer. 2009 Mar;9(3):167-81
references.pmid: 19238149
references.citation: Br J Cancer. 2008 Oct 21;99(8):1269-75
references.pmid: 18854825
references.citation: Ann Oncol. 2008 Feb;19(2):327-31
references.pmid: 18065408
references.citation: Int J Gynecol Cancer. 2002 Nov-Dec;12(6):715-9
references.pmid: 12445248
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7781-9
references.pmid: 19047105
references.citation: Scand J Gastroenterol. 2008;43(7):774-86
references.pmid: 18584515
references.citation: Scand J Gastroenterol. 2002 Apr;37(4):373-9
references.pmid: 11989825
references.citation: J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9
references.pmid: 12953086
references.citation: J Clin Oncol. 1989 Nov;7(11):1667-71
references.pmid: 2681555
references.citation: Gynecol Oncol. 2006 Nov;103(2):512-7
references.pmid: 16750560
references.citation: Gynecol Oncol. 1999 Aug;74(2):235-40
references.pmid: 10419737
references.citation: Cancer. 2005 Apr 15;103(8):1676-84
references.pmid: 15754326
references.citation: Crit Rev Oncol Hematol. 2004 Mar;49(3):187-98
references.pmid: 15036259
references.citation: Clin Cancer Res. 1995 Aug;1(8):899-906
references.pmid: 9816060
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3919-26
references.pmid: 15173101
references.citation: Obstet Gynecol. 1998 Sep;92(3):360-3
references.pmid: 9721770
references.citation: Anticancer Res. 2000 Nov-Dec;20(6D):5109-12
references.pmid: 11326678
references.citation: N Engl J Med. 1983 Oct 13;309(15):883-7
references.pmid: 6310399
references.citation: Cancer Lett. 1997 Nov 25;120(1):109-15
references.pmid: 9570393
references.citation: Gynecol Oncol. 2005 Nov;99(2):267-77
references.pmid: 16061277
references.citation: Clin Cancer Res. 2008 May 15;14(10):3030-5
references.pmid: 18483368
references.citation: Anticancer Res. 2004 May-Jun;24(3b):1973-9
references.pmid: 15274387
references.citation: Eur J Cancer. 2006 Aug;42(12):1889-96
references.pmid: 16809030
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references.pmid: 18024863
references.citation: Eur J Cancer. 2003 Sep;39(13):1948-56
references.pmid: 12932675
references.citation: Cancer Treat Res. 2000;103:57-75
references.pmid: 10948442
references.citation: J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70
references.pmid: 9293916
references.citation: Clin Cancer Res. 2002 Oct;8(10):3193-7
references.pmid: 12374688
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references.pmid: 18024865
references.citation: Acta Oncol. 2008;47(4):580-90
references.pmid: 18465326
references.citation: Clin Cancer Res. 1997 May;3(5):647-51
references.pmid: 9815732
references.citation: Am J Obstet Gynecol. 1989 Mar;160(3):667-71
references.pmid: 2648838
references.citation: J Clin Oncol. 2008 Jun 1;26(16):2653-8
references.pmid: 18443351
references.citation: Anticancer Res. 2004 Mar-Apr;24(2C):1149-57
references.pmid: 15154640
references.citation: Gynecol Oncol. 2002 Apr;85(1):108-13
references.pmid: 11925128
references.citation: J Biol Chem. 1992 Mar 5;267(7):4583-91
references.pmid: 1311314
references.citation: Gynecol Oncol. 2004 Jul;94(1):74-9
references.pmid: 15262122